NCT06499285 2026-03-11
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
Phase 3 Recruiting
Clinical Trials
86 trialsNCT05320198 2026-03-09
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
Phase 1/2 Recruiting
NCT04582539 2025-10-22
LIMBER
Incyte Corporation
Phase 1/2 Terminated
NCT04717414 2025-07-10
INDEPENDENCE
Celgene
Phase 3 Active not recruiting
NCT06737081 2024-12-17
SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT01284348 2024-08-29
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT03733249 2023-09-26
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT00931606 2023-09-13
MK-7962-012
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT03194542 2023-08-24
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
Celgene
Phase 2 Completed
NCT05704894 2023-01-30
Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens
Blau Farmaceutica S.A.
Phase 3 Unknown
NCT01736683 2022-10-24
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04076943 2022-06-03
Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Kyntra Bio
Phase 2 Completed
NCT01100879 2022-05-09
AOC-MM
Vifor Pharma
Phase 4 Terminated
NCT02631070 2021-12-17
MEDALIST
Celgene
Phase 3 Completed
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT02930850 2019-04-08
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
Masimo Corporation
Phase NA Completed
NCT03776032 2018-12-20
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy
Amgen
Phase 3 Completed
NCT01340976 2018-10-03
A Phase 1 Study of LY2787106 in Cancer and Anemia
Eli Lilly and Company
Phase 1 Completed
NCT02761642 2018-08-24
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
Hoffmann-La Roche
Phase 2 Completed
NCT00338286 2018-03-19
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT00236951 2018-02-20
Intravenous (IV) Iron vs. No Iron as the Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy
American Regent, Inc.
Phase 3 Completed
NCT00711958 2017-09-05
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
Sandoz
Phase 3 Completed
NCT00776425 2017-07-02
A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies
Hoffmann-La Roche
Phase 4 Completed
NCT02767765 2017-04-04
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
Hoffmann-La Roche
Phase 3 Completed
NCT00495378 2016-12-20
RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia
Ortho Biotech Products, L.P.
Phase 4 Terminated
NCT02554942 2016-11-02
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
Hoffmann-La Roche
Phase 4 Completed
NCT02564094 2016-11-02
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies
Hoffmann-La Roche
Phase 4 Completed
NCT02608060 2016-11-02
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
Hoffmann-La Roche
Phase 4 Terminated
NCT02624141 2016-11-02
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
Hoffmann-La Roche
Phase 4 Terminated
NCT01374373 2016-04-07
Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia
Bio Sidus SA
Phase 4 Completed
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT01691040 2014-06-26
Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer
TME Pharma AG
Phase 2 Completed
NCT00401544 2014-01-29
Darbepoetin Alfa With or Without Intravenous (IV) Iron
Amgen
Phase 2 Completed
NCT00989092 2014-01-29
Darbepoetin Alfa and Anemia of Cancer
Amgen
Phase 2 Terminated
NCT01101399 2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3 Completed
NCT00386152 2013-07-19
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00144131 2013-05-24
Flexibility: A Study to Assess the Impact of Darbepoetin Alfa in Subjects withNon-Myeloid Malignancies With Anemia Due to Chemotherapy
Amgen
Phase 2 Completed
NCT00148421 2013-05-15
Study for the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Multicycle Chemotherapy.
Amgen
Phase 3 Completed
NCT00035607 2013-05-13
Chemotherapy Related Anemia
Amgen
Phase 2 Completed
NCT00091858 2013-05-08
Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer
Amgen
Phase 3 Completed
NCT00111462 2013-05-08
Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy
Amgen
Phase 2 Completed
NCT00540384 2013-05-08
Dose-finding Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Subjects With Solid Tumours Receiving Multicycle Chemotherapy
Amgen
Phase 1/2 Completed
NCT00118638 2013-04-29
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Amgen
Phase 3 Completed
NCT00540696 2013-04-26
Study to Develop a Screening Tool for Functional Capacity in Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy and Darbepoetin Alfa
Amgen
Phase 2 Completed
NCT00097747 2012-12-21
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers
Affymax
Phase 1 Completed
NCT00272662 2012-12-21
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
Affymax
Phase 2 Completed
NCT00359840 2012-08-31
A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT01394991 2012-04-05
A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4 Completed
NCT00224068 2012-03-02
Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
Watson Pharmaceuticals
Phase 4 Completed
NCT00629876 2011-12-01
A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.
Takeda
Phase 1 Terminated